Low-level arsenic causes proteotoxic stress and not oxidative stress
نویسندگان
چکیده
منابع مشابه
Aneuploidy causes proteotoxic stress in yeast.
Gains or losses of entire chromosomes lead to aneuploidy, a condition tolerated poorly in all eukaryotes analyzed to date. How aneuploidy affects organismal and cellular physiology is poorly understood. We found that aneuploid budding yeast cells are under proteotoxic stress. Aneuploid strains are prone to aggregation of endogenous proteins as well as of ectopically expressed hard-to-fold prote...
متن کاملArsenic and Oxidative Stress in Pentylenetetrazole-induced Seizures in Mice
Background and Objective: Chronic arsenic toxicity is a widespread problem; the role of brain oxidative stress has been suggested in the genesis of epilepsy and in the post-seizure neuronal death. However, studies investigating the effects of arsenic on seizure and related mechanisms are limited. The purpose of this study was to examine the effect of prolonged exposure to sodium arsenite on oxi...
متن کاملOxidative Stress: Causes and Consequences
OXYGEN IS ESSENTIAL TO NORMAL BRAIN FUNCTION, but sometimes, like Kentucky bourbon, too much of a good thing is detrimental. In particular, reactive oxygen species (ROS) and reactive nitrogen species (RNS), although important in neuronal signaling and physiology at low levels, can, at higher levels, lead to neuronal dysfunction and death (4). Some aspects of free radical chemistry applicable to...
متن کاملLow level lead exposure and oxidative stress: current opinions.
Lead continues to pose a serious threat to the health of many children as well as adults. Concern about lead exposure as a significant public health problem has increased as evidence has mounted regarding adverse health effects at successively lower levels. This issue is complicated by the fact that there is no demonstrated biological function of lead in human. Lead potentially induces oxidativ...
متن کاملProteotoxic stress targeted therapy (PSTT)
About a decade ago a multiple myeloma patient demonstrated a complete response to a proteasome inhibitor Bortezomib. This case generated a lot of hopes, and after successful clinical trials Bortezomib was approved by FDA and became the drug of choice for this disease. A high sensitivity of multiple myeloma to proteasome inhibition is probably related to extensive production immunoglobulins by t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Toxicology and Applied Pharmacology
سال: 2018
ISSN: 0041-008X
DOI: 10.1016/j.taap.2018.01.014